1. Home
  2. ALLR vs IRIX Comparison

ALLR vs IRIX Comparison

Compare ALLR & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLR
  • IRIX
  • Stock Information
  • Founded
  • ALLR 2004
  • IRIX 1989
  • Country
  • ALLR United States
  • IRIX United States
  • Employees
  • ALLR N/A
  • IRIX N/A
  • Industry
  • ALLR Biotechnology: Pharmaceutical Preparations
  • IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ALLR Health Care
  • IRIX Health Care
  • Exchange
  • ALLR Nasdaq
  • IRIX Nasdaq
  • Market Cap
  • ALLR 15.8M
  • IRIX 16.5M
  • IPO Year
  • ALLR N/A
  • IRIX 1996
  • Fundamental
  • Price
  • ALLR $0.94
  • IRIX $1.24
  • Analyst Decision
  • ALLR Strong Buy
  • IRIX
  • Analyst Count
  • ALLR 1
  • IRIX 0
  • Target Price
  • ALLR $9.00
  • IRIX N/A
  • AVG Volume (30 Days)
  • ALLR 367.8K
  • IRIX 126.0K
  • Earning Date
  • ALLR 08-15-2025
  • IRIX 08-12-2025
  • Dividend Yield
  • ALLR N/A
  • IRIX N/A
  • EPS Growth
  • ALLR N/A
  • IRIX N/A
  • EPS
  • ALLR N/A
  • IRIX N/A
  • Revenue
  • ALLR N/A
  • IRIX $49,744,000.00
  • Revenue This Year
  • ALLR N/A
  • IRIX $9.61
  • Revenue Next Year
  • ALLR N/A
  • IRIX N/A
  • P/E Ratio
  • ALLR N/A
  • IRIX N/A
  • Revenue Growth
  • ALLR N/A
  • IRIX 0.09
  • 52 Week Low
  • ALLR $0.61
  • IRIX $0.78
  • 52 Week High
  • ALLR $6.00
  • IRIX $2.04
  • Technical
  • Relative Strength Index (RSI)
  • ALLR 47.03
  • IRIX 51.69
  • Support Level
  • ALLR $0.85
  • IRIX $1.11
  • Resistance Level
  • ALLR $1.01
  • IRIX $1.29
  • Average True Range (ATR)
  • ALLR 0.05
  • IRIX 0.08
  • MACD
  • ALLR -0.01
  • IRIX -0.01
  • Stochastic Oscillator
  • ALLR 47.55
  • IRIX 62.96

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Share on Social Networks: